IRIDEX CORP
No enriched coverage for $IRIX in the last 7 days.
No SEC Form 4 filings for $IRIX in the last 30 days.
See all $IRIX insider activity →Iridex (IRIX) said it expanded its EyeProGPO offering by adding EndoProbe Handpieces, giving more than 4,300 EyeProGPO members preferred pricing. The single-use handpieces are designed for use with Iridex laser consoles for retinal disorder treatment, with multiple models and gauge options. IRIX stock was $0.91.
IRIDEX CORP (IRIX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K IRIDEX CORP NASDAQ false 0001006045 0001006045 2026-07-10 2026-07-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 10, 2026 (Date of Report (date of e
Dizon Romeo R (Chief Financial Officer) purchased 975 shares of IRIDEX CORP (IRIX) at $1.14 on 2026-06-12.
Recent IRIX coverage spans insider activity, financial news and technology.
The article is a product-distribution expansion via EyeProGPO, likely modest near-term revenue impact but supportive for adoption of Iridex retinal laser consumables.
The filing is primarily governance and process disclosure, with limited direct implications for near-term fundamentals.
Insider buying is disclosed via SEC Form 4, but the transaction is small and lacks a new fundamental catalyst.
This is a small insider open-market buy by the CFO; it may modestly support sentiment but is unlikely to be a standalone catalyst.
An insider open-market buy is mildly supportive sentiment, but the disclosed size is small and lacks a direct fundamental catalyst.
alphai scores every news story that mentions IRIX with an AI model for sentiment and relevance, and aggregates insider trades from IRIDEX CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Iridex (IRIX) said it expanded its EyeProGPO offering by adding EndoProbe Handpieces, giving more than 4,300 EyeProGPO members preferred pricing. The single-use handpieces are designed for use with Iridex laser consoles for retinal disorder treatment, with multiple models and gauge options. IRIX stock was $0.91.
3 min readIRIDEX CORP (IRIX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K IRIDEX CORP NASDAQ false 0001006045 0001006045 2026-07-10 2026-07-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 10, 2026 (Date of Report (date of e
4 min readDizon Romeo R (Chief Financial Officer) purchased 975 shares of IRIDEX CORP (IRIX) at $1.14 on 2026-06-12.
2 min readDizon Romeo R (Chief Financial Officer) purchased 1,675 shares of IRIDEX CORP (IRIX) at $1.14 on 2026-06-11.
1 min readDizon Romeo R (Chief Financial Officer) purchased 2,400 shares of IRIDEX CORP (IRIX) at $1.12 on 2026-06-08.
1 min readDizon Romeo R (Chief Financial Officer) purchased 2,521 shares of IRIDEX CORP (IRIX) at $1.15 on 2026-06-05.
1 min readDizon Romeo R (Chief Financial Officer) purchased 2,400 shares of IRIDEX CORP (IRIX) at $1.17 on 2026-06-03.
2 min readDizon Romeo R (Chief Financial Officer) purchased 5,004 shares of IRIDEX CORP (IRIX) at $1.00 on 2026-05-26.
1 min readIRIDEX Corporation reported its Q1 2026 earnings, with revenues of $11.8 million, essentially flat year-over-year, and beating EPS expectations with a reported $-0.03 against an expected $-0.07. The company's glaucoma business, particularly G-Probes, showed strong growth, but international retina sales were impacted by regulatory and supply chain issues. Despite these challenges, IRIDEX reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million and expects to achieve positive cash flow from operations for the full year.
2 min readMOUNTAIN VIEW, Calif., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Iridex Corporation ( Nasdaq: IRIX ) , a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial ...
3 min read
